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Abstract 
 
 Septic shock is characterized by circulatory compromise, microcirculatory alterations and 
mitochondrial damage, which all reduce cellular energy production. In order to reduce the risk of major 
cell death and a diminished likelihood of recovery, adaptive changes appear to be activated. As a result, 
cells and organs may survive in a non-functioning hibernation-like condition. Sepsis-induced cardiac 
dysfunction may represent an example of such functional shutdown.  
 Sepsis-induced myocardial dysfunction is common, corresponds to the severity of sepsis, and 
is reversible in survivors. Mechanisms of sepsis-induced cardiac dysfunction include the attenuation of 
the adrenergic response at the cardiomyocyte level, alterations of intracellular calcium trafficking and 
blunted calcium sensitivity of contractile proteins. All these changes are mediated by cytokines.  
 Treatment of sepsis-induced cardiac dysfunction includes preload optimization with sufficient 
fluids. However, excessive volume loading is harmful. The first line vasopressor recommended at 
present is norepinephrine, while vasopressin can be started as a salvage therapy for those not 
responding to catecholamines. During early sepsis, cardiac output can be increased by dobutamine. 
While early administration of catecholamines might be necessary to restore adequate organ perfusion 
and pressure, prolonged administration might be harmful. 
 Novel therapies for sepsis-induced cardiac dysfunction are discussed in this article. Cardiac 
inotropy can be increased by levosimendan, istaroxime or omecamtiv mecarbil without greatly 
increasing cellular oxygen demands. Heart rate reduction with ivabradine will reduce myocardial 
oxygen expenditure and ameliorate diastolic filling. Beta-blockers additionally reduce local and 
systemic inflammation. Advances may also come from metabolic interventions such as pyruvate, 
succinate or high dose insulin substitutions. However, all these potentially advantageous concepts 
require rigorous testing before implementation in routine clinical practice.  
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Introduction 
 
  The aim of this article is to provide an overview on the underlying mechanisms of sepsis-
induced cardiac dysfunction and its management. Particular attention will be paid to unraveling clinical 
paradoxes and to identify the hierarchy of mechanistic events, as the correct understanding of 
mechanisms is crucial for the clinical management of affected patients. Finally, novel and potentially 
interesting therapies of sepsis-induced cardiomyopathy will be discussed.  
 
Sepsis and septic shock 
 
PAMPs and DAMPs 
 When microorganisms invade the host, pathogen associated molecular patterns (PAMPs) such 
as lipopolysaccharides (endotoxins) from Gram negative bacteria are recognized by immune cells [1]. 
The binding of PAMPs with particular receptors on the cell surface activates an intracellular cascade 
[2, 3]. This results in up- or down-regulation of specific genes encoding for a variety of proteins 
including cytokines and other inflammatory mediators and receptors [4]. The spread from local 
infection to sepsis depends on the severity of infection and the degree of inflammatory response [5]. In 
the most severe cases, shock develops as a result of decreased vascular tone, enhanced vascular 
permeability and sepsis-induced cardiomyopathy, leading to low stroke volume, low arterial blood 
pressure and, finally, impaired organ perfusion [6]. Tissue hypoperfusion is aggravated by 
microcirculatory disturbances [7-9]. If untreated, persistent shock causes cellular injury and the 
liberation of damage associated molecular patterns (DAMPs) such as mitochondrial proteins, adenosine 
or uric acid [10-12]. Like PAMPs, DAMPs have the potential to activate inflammation, creating a 
vicious spiral (Figure 1). If untreated, a point of no return is reached after which cell death pathways 
are activated, finally leading to the host’s demise. This point is influenced by host characteristics such 
as age, gender [13], co-morbidities [14] and genetic background [15] as well as infection properties 
such as the site of infection and pathogen virulence [5]. We and others believe that the final outcome is 
already predetermined at an early stage of the disease process [16], resulting in three patient groups:. 
The first is a survivor group who will likely live, even without therapy. The key message for their 
management is “first do no harm”[17]. The second group consists of non-survivors whose fate is pre-
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determined, and where intensive care will only delay their demise. The intermediate group includes 
those patients who would die without treatment, but who can be saved by appropriate therapy.  
 
Multiple organ dysfunction syndrome 
 Sepsis impacts the entire organism in a time-dependent manner [18]. This syndrome can affect 
all organ systems including the cardiovascular system [19], autonomic nervous system [20-22], 
endocrine system [23], metabolism [24] and bioenergetics [25]. During septic shock, circulatory 
compromise and mitochondrial damage [26-28] reduce intra-cellular ATP production and place the 
cells at risk of bio-energetic failure and cell death. In order to reduce the risk of cell death, adaptive 
changes may be activated [29]. Cellular functions are reduced, perhaps in order to limit energy 
expenditure, thereby creating a new equilibrium between energy supply and consumption [30]. As a 
result, the organs may survive in a non-functioning hibernation-like condition. Consequently, extensive 
tissue necrosis is not a characteristic of sepsis-induced organ dysfunction [31-33]. When the 
inflammatory process is overcome, cellular energy generation can improve, leading to resumption of 
normal cell processes and functional recovery [34]. 
 
The heart in sepsis 
 
Clinical evidence of sepsis-induced cardiomyopathy 
 Cardiac dysfunction is a well-recognized organ manifestation during sepsis and septic shock 
[35]. The involvement of the heart varies according to the timing and severity of the sepsis syndrome. 
During the very early phase of the disease, an echo-derived left-ventricular (LV) ejection fraction (EF) 
>55% is indicative of sepsis, as demonstrated in a retrospective evaluation of shock patients in the 
emergency room [36]. This might be explained by increased cardiac contractility due to adrenergic 
stimulation. Importantly, despite this high LVEF, stroke volume at this timepoint is low because of 
insufficient cardiac preload due to a high vascular permeability and low vascular tone. The 
compensatory rise in heart rate is often insufficient to maintain adequate cardiac output during this very 
early phase of sepsis, as demonstrated by elevated lactate levels and a low central venous oxygen 
saturation (ScvO2) [6].  
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 Jardin et al assessed 90 septic shock patients (28-day mortality of 62 %) during the later phase 
of sepsis [37]. Non-survivors had higher severity scores (SAPS 68 vs 52) and were given more fluid 
(5.2 L/day vs 4.1 L/day) than survivors but, nevertheless, had lower end-diastolic volumes suggesting a 
persistent preload deficiency. After fluid loading LVEF was markedly decreased in all patients. 
However, by the time of discharge from the intensive care unit, LVEF had normalized in survivors. 
The pronounced systolic dysfunction in septic patients and the reversibility of the phenomenon in 
sepsis survivors was published previously in a seminal paper by Parker et al [38]. More recently, 
Vieillard-Baron and co-workers found that 40 of 67 (60%) septic shock patients developed a LVEF 
<45% during the first 3 days of haemodynamic support. It can be concluded that LV systolic 
dysfunction is common in septic patients and potentially reversible in survivors.  
 
 Several studies have provided evidence for diastolic dysfunction during sepsis [39-42]. 
Landsberg et al investigated 262 patients with severe sepsis and septic shock (30 day mortality of 30%) 
by echocardiography [43]. Again, lower LV end-diastolic volumes and stroke volumes were seen in 
eventual non-survivors. In addition, diastolic dysfunction was common, and was associated with age, 
pre-existing hypertension and diabetes mellitus, and strongly correlated with an adverse outcome. 
Patients with systolic dysfunction (LVEF ≤50 %) and/or diastolic dysfunction had a higher mortality 
[43]. It can be concluded that the severity of sepsis corresponds to the degree of organ involvement in 
general, and cardiac impairment in particular. 
 
 Other clinical aspects of sepsis-induced cardiac dysfunction are tachyarrhythmias [44, 45], 
right heart failure [46, 47], elevated troponin [48, 49] and B-type natriuretic peptide levels [50-52].  
 
 While some studies suggest that the presence of cardiac dysfunction is a risk factor for 
adverse outcomes [43], other reported more cardiac depression in sepsis survivors compared to non-
survivors [37, 38]. How can such conflicting results be explained? Clearly, the development of cardiac 
dysfunction requires some degree of inflammation. Hence, mild cardiac dysfunction might result from 
mild systemic inflammation, and therefore be a good prognostic sign. In very sick septic patients the 
presence of profound myocardial depression defined by a low LVEF may represent preload 
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optimization and good adaptation, while a normal LVEF could be caused by persistent preload 
deficiency [37] and/or ongoing harmful adrenergic over-stimulation. 
 
Underlying mechanisms 
 Mechanisms of sepsis-induced cardiac dysfunction have been reviewed extensively [35, 53-
59]. Early sepsis is characterized by high levels of circulating catecholamines [20, 60, 61] that derive 
from the autonomous nervous system, the gut [62], lymphocytes [63, 64] macrophages [65] and 
neutrophils [66, 67]. A major mechanism of sepsis-induced cardiac dysfunction is the attenuation of the 
adrenergic response at the cardiomyocyte level due to down-regulation of β-adrenergic receptors [68, 
69] and depression of post-receptor signaling pathways [70-73]. These changes are mediated by 
cytokines [74, 75] and nitric oxide [76, 77]. Blunting of the adrenergic response is probably enhanced 
by neuronal apoptosis in the cardiovascular autonomic centres [78], and by inactivation of 
catecholamines by reactive oxygen species [79].  
 
 High levels of circulating catecholamines due to ongoing endogenous and pharmacological 
adrenergic stimulation may partially explain the discrepancy between maintained cardiac contractility 
in vivo, that clinicians observe at the bedside, and the profound decrease in cardiac contractility seen 
under laboratory conditions, for example in ex vivo models of cultured myocardial cells [80] and 
isolated perfused hearts [81]. Adrenergic downregulation, however, results in a reduced cardiac reserve 
that is unraveled by a reversible hypo-responsiveness to dobutamine in patients with septic shock [82]. 
Finally, preload optimization and catecholamine-driven tachycardia can generate a high cardiac output 
despite profound intrinsic myocardial depression [83]. In can be concluded that myocardial depression 
can be present despite a hyperdynamic state in resuscitated patients with established sepsis. 
 
 Sepsis-induced myocardial dysfunction is characterized by altered intracellular calcium 
trafficking. Suppression of L-type calcium currents [84-87], decreases in ryanodine receptor density 
and activity [88-90], and changes of calcium re-uptake into the sarcoplasmic reticulum [91, 92] have 
all been demonstrated in sepsis models. On a myofibrillar level, sepsis affects the calcium sensitivity of 
contractile proteins [93-95]. These changes will impair both systolic and diastolic function, but it 
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remains to be determined how they relate to blunted β-adrenergic signaling and defective enzyme 
phosphorylation.  
 
 Severe infection leads to genetic reprogramming in myocardial cells. Using a fluid-
resuscitated rat model of fecal peritonitis we identified 527 genes whose transcription was significantly 
down or up-regulated as early as 6h after the septic insult [96]. Dos Santos and coworkers 
demonstrated the expression of genes favoring fetal isoforms of contraction-related proteins in an 
iNOS-dependent manner [97]. Those findings confirm early gene activation and –suppression on an 
organ level during sepsis. Future research must investigate how novel interventions affect these 
mechanisms and influence outcomes. 
 
Pharmacological support of the septic heart 
 
Early goal-directed therapy 
 A critical determinant in patients with septic shock is time to shock resolution, as the severity 
and duration of shock correlates with the degree of inflammation, organ dysfunction and adverse 
outcomes. The use of a 6-hour protocol with the pre-defined haemodynamic goals listed below 
accelerated haemodynamic stabilization and significantly reduced mortality from 57% to 42% in 
patients with severe sepsis and septic shock [6]. Crystalloids were given as 500 ml boluses every 30 
minutes to achieve a central venous pressure between 8-12 mmHg. Vasopressors or vasodilators were 
administered to maintain a mean arterial blood pressure between 65-90 mmHg. If the SvO2 remained 
<70 %, oxygen delivery was increased by transfusion of red blood cells to a haematocrit ≥30 %. If 
SvO2 still remained <70 %, dobutamine was added at a dose of 2.5-20 µg/kg body weight/min to 
increase cardiac contractility [6]. These measures were in addition to rapid diagnosis and treatment of 
the underlying infection by source control and antibiotic therapy [98]. This resuscitation care bundles is 
recommended at present in the Surviving Sepsis Campaign guidelines [99]. 
 
Fluids for preload 
 While early and sufficient fluid administration is likely to be beneficial, excessive volume 
loading is harmful [100, 101]. The risk of pulmonary oedema formation is particularly elevated due to 
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increased permeability of the pulmonary microcirculation and LV diastolic dysfunction [102]. 
Pulmonary oedema and concomitant hypoxaemia will cause vasoconstriction and increase pulmonary 
vascular resistance (= right ventricular afterload), potentially resulting in right ventricular deterioration 
with a fall in stroke volume and cardiac output. Depending on the fluids used, additional disadvantages 
include electrolyte disturbances with normal saline, the risk of renal failure with colloids [103-105], 
and high costs with albumin solutions [106].  
 
Inotropes for contractility 
 During early sepsis, a low SvO2 value and hyperlactataemia indicate an imbalance between 
oxygen delivery and demand [107]. After optimization of oxygenation, volume status and haematocrit, 
cardiac output can be increased by inotropes. The combination of norepinephrine and dobutamine may 
allow a better modulation of vascular and cardiac effects than epinephrine alone. However, a multi-
center study investigating 330 patients with septic shock revealed no differences regarding ICU length 
of stay and mortality between the two strategies [108]. Importantly, catecholamines and 
phosphodiesterase inhibitors (that also increase cAMP) have many adverse cardiac (arrhythmia, 
increased oxygen demands) and non-cardiac (hyperglycemia, muscle catabolism, stimulation of 
bacterial growth, immunosuppression) effects [109]. Accordingly, efforts to enhance cardiac index 
>4.5 l/min/m2 or elevate mixed venous oxygen saturation ≥70% by dobutamine administration during 
established sepsis with organ failure is not beneficial and may be even harmful [110, 111]. This 
underlines the importance of timing and dosing of therapeutic interventions. While early administration 
of catecholamines might be necessary to reverse shock and restore adequate organ perfusion, prolonged 
administration, particularly at unnecessarily high doses, might be harmful [17, 109].  
 Milrinone and other phosphodiasterase III inhibitors have been used to stimulate the septic 
heart [112]. This approach might be useful if the patient is treated with β-blockers, as the adrenergic 
effect of milrinone does not come from β-receptor stimulation but via a decreased degradation of the 
second messenger cAMP. However, this group of agents also decreases vascular tone, consequently 
increasing the risks of arrhythmia and hypotension [113].  
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Vasopressors for organ perfusion pressure 
 The most commonly used vasopressor in septic patients is norepinephrine, which is 
administered at doses up to 1.0 µg/kg/min. In a direct comparison with dopamine, noradrenaline caused 
less arrhythmia [45] and less skin ischaemia [114, 115]. While catecholamines are effective in 
counteracting haemodynamic instability [116], excessive use might be harmful. In a retrospective 
analysis, mean arterial pressures maintained >70 mmHg were not associated with improved survival 
though mortality was progressively higher in those given increasing doses of vasopressor to achieve 
this [117].  
 Vasopressin (or synthetic analogues such as terlipressin) is not recommended as a first line 
treatment, but can be considered as a salvage therapy [118, 119]. Vasopressin infusion rates up to 0.01-
0.04 U/min are generally considered safe when norepinephrine infusion rate exceeds 0.5 µg/kg/min. 
Future studies are needed to identify the lowest acceptable mean arterial blood pressure in individual 
patients that is still compatible with adequate tissue perfusion pressures yet avoids unnecessary high 
vasopressor administration. More important than simply targeting arterial blood pressure, clinicians 
should try to assess the adequacy of organ perfusion in their sick patients and treat accordingly. 
 
Novel therapies for the septic heart 
 
Novel inotropes 
 The beneficial short-term effect of enhanced contractility by cAMP-elevating drugs (e.g. 
dobutamine, milrinone) is, at least partly, abolished by increased energy consumption at the cellular 
level [120]. This might explain the lack of favorable long-term outcomes with prolonged use of these 
drugs in critically ill patients [121]. Hence, novel inotropes are urgently needed.  
 
  Levosimendan is a calcium sensitizer that ameliorates contractility with relatively little rise in 
cellular oxygen demands [122-124]. It increases calcium affinity at the level of troponin C, thereby 
improving cross-bridge kinetics between actin and myosin [125]. Levosimendan improves contractility 
without compromising diastolic function. The drug has been successfully used in both preclinical 
sepsis models [126, 127] and in patients with septic shock [128]. As the molecule does not interact 
with β-adrenoreceptors, levosimendan might be particularly useful when β-blockers are administered 
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(see below). Levosimendan also induces beneficial preconditioning via ATP-dependent potassium 
channels [129]. However, the same mechanism also causes vasodilation, which may limit its use in 
patients with septic shock [130]. 
 
 Promising new intoropic drugs that have been developed for patients with heart failure are of 
potential interest for patients with sepsis-related myocardial depression [125]. Istaroxime represents a 
new class of Na+/K+-ATPase inhibitors and stimulates SERCA, thereby exhibiting inotropic and 
lusitropic effects [131, 132]. In animal models, this new drug exerts inotropic activity comparable with 
that of digitalis but produces less arrhythmia [133]. Initial clinical trials demonstrated a good safety 
profile, though future studies are needed before the drug can be considered for clinical use.  
 
 Omecamtiv mecarbil is a direct activator of the cardiac myosin-ATPase, thereby increasing 
the transition of myosin into the actin-bound force generating state [134]. Importantly, improvements 
in cardiac contractility were not associated with increased intracellular calcium transients nor with 
increased myocardial oxygen consumption [125]. First clinical studies demonstrated a dose-related 
increase in cardiac contractile function without clinically relevant changes in diastolic function [135, 
136]. However, as omecamtiv mecarbil increases contractility by prolonging systolic ejection time, 
cardiac filling might be impaired at higher heart rates (as usually observed in septic patients). 
 
Beta-blockers in sepsis 
 As adrenergic over-stimulation may contribute to the clinical deterioration and poor outcome 
of septic patients [61, 66, 137], several groups have tested β-blockers in septic animals and patients 
(see [30, 138-140] for reviews). In septic animals, β-blockers reduced heart rate though stroke volume 
was preserved [81, 141]. The longer duration of diastole may perhaps allow better diastolic filling. In a 
pig model of endotoxic shock, the infusion of the short-acting β1 antagonist esmolol even improved 
stroke volume over time compared to control animals [142]. Despite reducing heart rate by 
approximately 20%, no septic animal suffered from cardiovascular collapse during the esmolol 
infusion period [142]. Initial preliminary studies in humans demonstrate that intravenous esmolol 
administration is feasible in patients with septic shock [143]. Beta-blockers also reduced plasma levels 
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of pro-inflammatory cytokines such as TNF-α and IL-6 [81, 141, 144]. In rats with fecal peritonitis, an 
esmolol infusion reduced the local inflammatory response as well as bacterial translocation from the 
gut into mesenteric lymph nodes [145]. Survival times of septic animals have been prolonged in several 
animal studies [141, 145, 146]. Small clinical studies in septic patients revealed similar haemodynamic 
and inflammatory results with β-blockers [147-149]. Despite these promising results, more research is 
required to unravel clinically important questions before β-blockers can be recommended for routine 
use in septic patients. If patient selection, β-blocker dose and timing of administration are wrongly 
selected, harm might ensue, as has been observed in patients with acute myocardial infarction [150] or 
in patients undergoing non-cardiac surgery [151]. 
 
 Heart rate reduction considerably lowers cardiac energy demands, thereby creating a better 
balance between myocardial energy generation and expenditure in conditions of impaired energy 
production [30]. Ivabradine, a funny channel blocker, can accomplish heart rate modulation without 
negative inotropism. This drug affects If –currents in myocardial cells producing a heart rate reduction 
during sinus rhythm. First results in patients with heart failure are promising [152, 153]. Currently, a 
clinical trial investigating the administration of ivabradine to patients with multiple organ dysfunction 
syndrome is being performed [154]. 
 
Metabolic interventions 
 Sepsis causes profound metabolic changes and places vital organs at risk of energy failure 
[24]. Several strategies have been elucidated in order to reduce the cellular energy crisis. For example, 
pyruvate substitution has been evaluated as a cellular ATP provider. In aerobic conditions, pyruvate is 
efficiently metabolized in the Krebs cycle. Under anaerobic conditions, it is converted to lactate at a 
much lower ATP yield. Therapeutic pyruvate administration increased myocardial energy availability, 
particularly to the SERCA, resulting in improved intracellular calcium handling [155]. It should 
however be noted that pyruvate has separate immunomodulatory properties that may also play an 
important role. 
 
 Sepsis causes mitochondrial dysfunction, particularly affecting complex I of the respiratory 
chain [26, 156]. Succinate serves as a substrate for complex II and could potentially bypass a 
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dysfunctional complex I, hence improving mitochondrial oxygen utilization and ATP production [157, 
158]. Sepsis survival appears to require mitochondrial recovery by mitochondrial biogenesis [34]. This 
process depends, among other factors, on nitric oxide [159].  
 
 Elevated glucose levels are common in septic patients and represent an additional danger to 
cellular and mitochondrial integrity [160]. Hence, maintenance of normoglycaemia with insulin 
substitution improved outcomes in critically ill patients [161, 162]. A more liberal strategy aiming at 
blood glucose levels between 4.5-10.0 mmol/l was shown to be safer than a tighter control because of a 
lower incidence of hypoglycaemic episodes [163].  
 
 Insulin fuels glucose transport into the cardiomyocytes and intensifies cardiac inotropy [164]. 
Although glucose-insulin-potassium infusion (with insulin doses <0.2 U/kg/h) did not provide 
additional benefit in patients with myocardial infarction [165, 166], this regimen might still be an 
interesting option in sepsis-induced myocardial dysfunction [167, 168]. In patients with β-blocker or 
calcium channel-blocker poisoning, very high doses of insulin (0.5-10 U/kg/ h) have been used 
successfully to stimulate cardiac contractility [164, 169, 170]. First experiments in endotoxemic pigs 
with such high insulin dosages are also promising [171]. However, more research is needed before this 
concept can be applied to septic patients.  
 
Conclusions 
 
 Sepsis-induced cardiac dysfunction is caused by a functional shutdown in a situation where 
energy requirements do not meet energy demands. The phenomenon is common, corresponds to the 
severity of sepsis, and is reversible in survivors.  
 Current treatment recommendations aim at increasing oxygen delivery to peripheral tissues. 
While fluids, vasopressors and β1-adrenergic agonists may be necessary to restore organ perfusion and 
pressures in the early phase of sepsis, the same options may be harmful later on.  
 
 Potentially useful therapies for sepsis-induced cardiac dysfunction include novel inotropes 
that increase contractility without a large effect on cellular oxygen demands. Heart rate reduction 
 - 14 - 
Alain Rudiger & Mervyn Singer: The heart in sepsis 
further reduces cardiac oxygen expenditure and improves diastolic filling. Beta-blockers additionally 
reduce local and systemic inflammation. Important advances may also come from other metabolic 
interventions. However, all these potentially advantageous concepts require rigorous preclinical and 
clinical testing before implementation in the clinical routine.  
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Figures 
 
Figure 1:  
 
 
DAMP damage-associated molecular pattern; MOF multiple organ failure; PAMP pathogen-associated 
molecular pattern; SIRS systemic inflammatory response syndrome (for details see text) 
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